Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver (Q38443159)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver |
scientific article |
Statements
1 reference
Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver (English)
1 reference
Amit S Kalgutkar
1 reference
Heather L Hatch
1 reference
Frederick Kosea
1 reference
Hang T Nguyen
1 reference
Edna F Choo
1 reference
Kim F McClure
1 reference
Timothy J Taylor
1 reference
Kirk R Henne
1 reference
Alexander V Kuperman
1 reference
Mark A Dombroski
1 reference
Michael A Letavic
1 reference
1 November 2006
1 reference
1 reference
Identifiers
1 reference